NCT07677384尚未招募3 期
A Multicenter, Open-label, Phase 3 Study to Evaluate the Short-term and Long-term Safety of HS-10506 in Chinese Adult Patients With Insomnia Disorder
Jiangsu Hansoh Pharmaceutical Co., Ltd.0 个研究点目标入组 600 人开始时间: 2026年6月12日最近更新:
适应症
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 600
- 主要终点
- Incidence and severity of adverse events (AE)
研究概览
简要总结
The primary purpose of this open-label phase Ⅲ study is to evaluate the safety of HS-10506 on the incidence and severity of adverse events (AE), serious adverse events (SAE), adverse events of special interest (AESI) in Chinese adult participants with insomnia disorder.
详细描述
The study will comprise 4 periods : a Screening Period, a Run-in Period, an Open-Label Treatment Period during which participants will be treated for 4, 24, 36, or 48 consecutive weeks and a minimum 7-day Follow-up Period before an End of Study (EOS) Visit. The total study duration for each participant on this study is 2-13 months.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Participants must be 18 to 65 years of age (inclusive 18, not inclusive 65);
- •Participants are required to voluntarily sign the informed consent form;
- •Body mass index (BMI): BMI (weight/height2 [kg/m2]) must be in the range of 18 to 35 kg/m2 (inclusive);
- •For Participants completed Study 301: Participants have completed the Study 301, can potentially benefit from extended treatment with HS-10506 and have no major safety risks according to the investigator's clinical judgment;
- •For new Participants: Participants must meet Diagnostic and Statistical Manual of Mental Disorders (5th edition) (DSM-5) criteria for insomnia disorder;
- •For new Participants: Participants must have Insomnia Severity Index (ISI) scores≥15 at screening;
- •For new Participants: Participants must have an sSOL≥30 minutes, sWASO≥30 minutes, and sTST<6.5 hours for at least three nights every week within one month prior to screening; and sSOL≥30 minutes, sWASO≥30 minutes, and sTST<6.5 hours for at least 3 nights from sleep diary in the last 7 consecutive days before the first dose in the open-label treatment period;
排除标准
- •Has received systemic hypnotherapy, cognitive behavioral therapy (CBT), or other non-pharmacological treatments for insomnia in last 4 weeks or have plans during the study;
- •Has a risk of suicide according to the Columbia Suicide Severity Rating Scale (C-SSRS), or has a high risk of suicide at the discretion of the investigator;
- •Has used any medication that may affect the pharmacokinetics of HS-10506 or GLP-1R-related single/multi-target drugs within the past 2 weeks or 5 half-lives of the medication;
- •Has used any medication that may affect sleep-wake function, or any other prohibited central nervous system active medications within 1 week or 5 half-lives of the medication;
- •Has a history of drug dependency or abuse within the past 1 year or showed positive in urine drug test at screening;
- •Has a history of alcohol abuse within the past 1 year or can't obey the rules of alcohol restriction;
- •Has a history of smoking≥10 cigars daily within the past 3 months or can't obey the rules of cigar restriction;
- •Has a history of caffeine consumption≥600 mg per day or can't obey the rules of caffeine restriction;
- •Has been working across 3 or more time zones or shift work within 2 weeks prior to screening;
- •Has taken more than 3 naps per week for>1 hour each time within the past 2 weeks prior to screening;
- •Has any circumstances or conditions, which, in the opinion of the investigator, may affect the subject's full participation in the study or compliance with the protocol.
- •For Participants completed Study 301: Has been diagnosed with a sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder during Study 301, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
- •For Participants completed Study 301: Has been diagnosed with neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or current chronic pain that affects sleep, nocturia resulting in frequent need to get out of bed to use the bathroom during the night; or clinically significant and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases during Study 301; or other systemic diseases that are inappropriate for the study;
- •For Participants completed Study 301: Previously participated in any clinical trial other than HS-10506-301 within 3 months prior to screening;
- •For new Participants: Has history of/current sleep-wake disorders or sleep-related breathing disorders other than insomnia disorder, such as restless legs syndrome, periodic limb movement disorder, circadian rhythm disorder, narcolepsy, rapid eye movement sleep phase (REM) behavioral disorders, and obstructive sleep apnea;
- •For new Participants: Has history of/current neurodevelopmental retardation, cognitive impairment, epilepsy, schizophrenia, bipolar disorder, hyperthyroidism, cancer, severe cardio-cerebrovascular diseases or respiratory diseases; or current chronic pain that affects sleep, nocturia resulting in frequent need to get out of bed to use the bathroom during the night; or clinically significant and/or unstable neurological, psychiatric, respiratory, cardiovascular, digestive, immunologic, urologic, endocrine diseases within the past 3 months prior to screening; or other systemic diseases that are inappropriate for the study;
- •For new Participants: Previously use of HS-10506;
- •For new Participants: Previously participated in any clinical trial within 3 months prior to screening.
结局指标
主要结局
Incidence and severity of adverse events (AE)
时间窗: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
An AE is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
Incidence and severity of serious adverse events (SAE)
时间窗: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
An SAE is any AE that results in: death, persistent or significant disability/incapacity, requires inpatient hospitalization or prolongation of existing hospitalization, is life-threatening experience, is a congenital anomaly/birth defect and may jeopardize participants and/or may require medical or surgical intervention to prevent one of the outcomes listed above.
Incidence and severity of adverse events of special interest (AESI)
时间窗: From date of signing the informed consent until the date of the end-of-study visit or early withdrawal, assessed up to 13 months
An AESI (serious or non-serious) is any medical event specific to the investigational product or clinical trial.
次要结局
- Rebound insomnia by subjective wake after sleep onset (sWASO) during the follow-up period(Baseline, Follow-up Period (7-9 days))
- Number of Participants With Clinically Significant Change in hematology(Baseline, Week 12, Week 24, Week 36, Week 48)
- Number of Participants With Clinically Significant Change in clinical chemistry(Baseline, Week 12, Week 24, Week 36, Week 48)
- Number of Participants With Clinically Significant Change in urinalysis(Baseline, Week 12, Week 24, Week 36, Week 48)
- Withdrawal symptoms by Physician Withdrawal Checklist (PWC-20)(The day after the last administration and at least 7 days after discontinuation of the medication)
- Rebound insomnia by subjective sleep onset latency (sSOL) during the follow-up period(Baseline, Follow-up Period (7-9 days))
- Rebound insomnia by subjective total sleep time (sTST) during the follow-up period(Baseline, Follow-up Period (7-9 days))
- Change from baseline in subjective sleep onset latency (sSOL) under the treatment of HS-10506(Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months))
- Change from baseline in subjective sleep efficiency (sSE) under the treatment of HS-10506(Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months))
- Change from baseline in subjective wake after sleep onset (sWASO) under the treatment of HS-10506(Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months))
- Change from baseline in subjective total sleep time (sTST) under the treatment of HS-10506(Baseline, every 4 weeks during Open-Label Treatment Period (up to 12 months))
研究者
相似试验
尚未招募
3 期
A Study of HS-10506 in Chinese Patients With Insomnia DisorderNCT07587385Jiangsu Hansoh Pharmaceutical Co., Ltd.732
已完成
不适用
Safety Evaluation of HORS-051511 in Healthy AdultsCTRI/2023/12/060476Himalaya Wellness Company (HWC)12
招募中
1 期
Phase I Study of HRS-3005 in B-cell MalignanciesNCT07556822Jiangsu HengRui Medicine Co., Ltd.190
招募中
1 期
Phase I Study of HRS-1635 in B-cell MalignanciesNCT07583212Chengdu Suncadia Medicine Co., Ltd.180
招募中
1 期
Study of Safety and Efficacy of HS-10542 in Patients With Paroxysmal Nocturnal HemoglobinuriaNCT07470762Jiangsu Hansoh Pharmaceutical Co., Ltd.50